GroPep gets European patent covering pregnancy-related conditions

By Elaine Rigoli

Tampa, Fla., July 26 - GroPep Ltd. has been granted European Patent No. 1028743, covering a method of treating recurrent miscarriage and preeclampsia using GroPep's infertility drug product, PV903.

The European patent, covered through 2018, complements two granted U.S. patents licensed to GroPep by OSI Pharmaceuticals that cover the active ingredient of PV903 and method of manufacture until at least 2020.

GroPep is developing PV903 as a potential treatment for recurrent miscarriage, which the company said has an estimated market potential of more than $750 million per year.

There are currently no drugs approved for the treatment of recurrent miscarriage, according to a news release.

GroPep is conducting a phase 1 clinical trial on PV903 to evaluate the safety and tolerability of vaginally administered PV903 gel and to determine whether PV903 has effects on vaginal immune cells in a manner consistent with its proposed role in treating immune-based infertility.

Results from the trial are expected during the second half of 2006 and if successful, GroPep will seek to partner PV903 with an international pharmaceutical or biotechnology company with an established franchise in reproductive medicine, the release said.

GroPep, based in Thebarton, Australia, develops biologically active proteins for cell culture and biomedical research.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.